Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis

HAOLING H. WENG, VEENA K. RANGANATH, DINESH KHANNA, MYUNGSHIN OH, DANIEL E. FURST, GRACE S. PARK, DAVID A. ELASHOFF, JOHN T. SHARP, RICHARD H. GOLD, JAMES B. PETER and HAROLD E. PAULUS
The Journal of Rheumatology March 2010, 37 (3) 550-557; DOI: https://doi.org/10.3899/jrheum.090818
HAOLING H. WENG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hollyweng@yahoo.com
VEENA K. RANGANATH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DINESH KHANNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MYUNGSHIN OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL E. FURST
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GRACE S. PARK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID A. ELASHOFF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN T. SHARP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICHARD H. GOLD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAMES B. PETER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAROLD E. PAULUS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To evaluate responses by time to initiation of nonbiologic disease-modifying antirheumatic drugs (DMARD) in a DMARD-naive cohort of patients with early seropositive rheumatoid arthritis (RA).

Methods. Subjects were categorized by the time from symptom onset to the first DMARD use (median 5.7 months, range 0.6–15.9). Subjects who started their first DMARD within 5 months of symptom onset were compared to subjects who started after 5 months. Disease Activity Scores (DAS-44) and total Sharp Score (TSS) progression rates were analyzed using Wilcoxon rank-sum and chi-square tests; multiple linear regression analysis adjusted for potential covariates. The slope of the least-squares regression line was calculated to estimate the annualized TSS progression rates.

Results. Of 233 RA patients, 76% were female and mean age was 50 (SD 13) years. At DMARD start, DAS-44 was similar in all subsets within the 0.6 to 15 months’ duration between symptom onset and DMARD initiation. Erosion scores tended to be higher in those who started DMARD later, but Health Assessment Questionnaire-Disability Index (HAQ-DI) scores were higher in those who started DMARD earlier. During the 2 years after DMARD initiation, improvements in HAQ-DI and DAS-44 were similar in the various duration subsets, with about 25% ever achieving DAS remission (DAS < 1.6). Radiographic progression tended to be numerically but not statistically more rapid in the earlier subsets.

Conclusion. Following initiation of nonbiologic DMARD therapy at various times within 15 months of symptom onset, improvements of DAS-44, HAQ-DI, remission rate, and radiographic progression rate were similar, although higher baseline erosion scores were present in those with later initiation of DMARD.

  • RHEUMATOID ARTHRITIS
  • DISEASE ACTIVITY SCORE
  • RADIOGRAPH
  • REMISSION
  • WINDOW OF OPPORTUNITY
  • DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Footnotes

  • The content of this report does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health.

  • Dr. Sharp is deceased; Dr. Peter is deceased.

  • Supported by NIH/NIAMS P60 AR 26834; Southern California Chapter of the Arthritis Foundation; Specialty Laboratories; and Oregon Arthritis Foundation. Dr. Khanna received support from the UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748. Dr. Ranganath received support from the ACR/REF CIFA and UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748.

    • Accepted for publication October 30, 2009.
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 3
1 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis
HAOLING H. WENG, VEENA K. RANGANATH, DINESH KHANNA, MYUNGSHIN OH, DANIEL E. FURST, GRACE S. PARK, DAVID A. ELASHOFF, JOHN T. SHARP, RICHARD H. GOLD, JAMES B. PETER, HAROLD E. PAULUS
The Journal of Rheumatology Mar 2010, 37 (3) 550-557; DOI: 10.3899/jrheum.090818

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis
HAOLING H. WENG, VEENA K. RANGANATH, DINESH KHANNA, MYUNGSHIN OH, DANIEL E. FURST, GRACE S. PARK, DAVID A. ELASHOFF, JOHN T. SHARP, RICHARD H. GOLD, JAMES B. PETER, HAROLD E. PAULUS
The Journal of Rheumatology Mar 2010, 37 (3) 550-557; DOI: 10.3899/jrheum.090818
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Appendix
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach
  • Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus
  • The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire